title: Statin use and the risk of kidney cancer: a population-based case-control study.
abstract: OBJECTIVE
  To investigate whether the use of statins was associated with kidney cancer risk.
  
  
  METHODS
  We conducted a population-based case-control study in Taiwan. Cases consisted of all patients who were aged 50 years and older, and had a first-time diagnosis of kidney cancer for the period between 2005 and 2009. The controls were matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multiple logistic regression.
  
  
  RESULTS
  We examined 177 kidney cancer cases and 708 controls. The adjusted OR for any statin prescription was 1.08 (95% CI = 0.70 - 1.67). Compared with no use of statins, the adjusted ORs were 0.91 (95% CI = 0.50 - 1.63) for the group having been prescribed statins with cumulative defined daily dose (DDDs) below 105 and 1.28 (95% CI = 0.73 - 2.23) for the group with cumulative statin use of 105 DDDs or more.
  
  
  CONCLUSIONS
  The present data do not provide evidence to support either beneficial or harmful associations between statin use and kidney cancer risk. However, there is a trend of increased kidney cancer risk with higher cumulative DDDs, and consequently that it is prudent to continue monitoring cancer incidence among long-standing statin users.
authors.affiliation: Kaohsiung Medical University, Institute of Pharmacology, College of Medicine, Kaohsiung, Taiwan.
authors.forename: Hui-Fen
authors.initials: HF
authors.lastname: Chiu
authors.forename: Chien-Chun
authors.initials: CC
authors.lastname: Kuo
authors.forename: Hsin-Wei
authors.initials: HW
authors.lastname: Kuo
authors.forename: I-Ming
authors.initials: IM
authors.lastname: Lee
authors.forename: Chien-Te
authors.initials: CT
authors.lastname: Lee
authors.forename: Chun-Yuh
authors.initials: CY
authors.lastname: Yang
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012306:Risk
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors